On May 22, 2024, Neophore Limited closed the transaction. The company amended the terms of the transaction and has received additional funds in its final tranche from new investor Bristol-Myers Squibb Company. The transaction was oversubscribed.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.04 USD | +0.56% |
|
-1.06% | -20.02% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.02% | 82.73B | |
+51.99% | 803B | |
-5.72% | 351B | |
+18.94% | 324B | |
+11.07% | 303B | |
+16.96% | 243B | |
+2.25% | 228B | |
+11.15% | 217B | |
+7.59% | 164B | |
-3.65% | 155B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Neophore Limited announced that it has received funding from a group of investors